Last edition
News about "siRNA therapeutics "
Ribo Submits Phase 2 EMA Trial Application for siRNA Therapy in Thromboembolic Disease
Ribo submits a Phase 2 clinical trial application to the European Medicines Agency (EMA) for its siRNA therapeutic targeting thromboembolic disease, advancing development of innovative oligonucleotide-based therapies for Coronary Artery Disease (CAD)
SiRNA Therapeutics | 28/05/2026 | By News Bureau
Hongene Biotech Supports SiranBio's Dual-Target siRNA Programme for Chronic Hepatitis B
Hongene Biotech provided end-to-end CDMO support for SiranBio’s SA1211 siRNA candidate, highlighting its capabilities in complex oligonucleotide therapeutic development and manufacturing.
SiRNA Therapeutics | 11/05/2026 | By News Bureau
GSK and Empirico Sign Licensing Deal for Respiratory Oligonucleotide
Oligonucleotide therapies, including siRNA, offer the potential to modulate gene expression and target diseases beyond the reach of traditional drugs. EMP-012 adds to GSK’s growing oligonucleotide pipeline across respiratory, immunology and inflammation, and infectious disease portfolios.
SiRNA Therapeutics | 29/10/2025 | By Dineshwori | 269
Argo Biopharma and Novartis Partner on Novel Cardiovascular Therapies
Argo to receive $160 million upfront as Novartis licenses pipeline assets, explores ANGPTL3 in dyslipidemia, and secures options for future siRNA candidates.
SiRNA Therapeutics | 05/09/2025 | By Dineshwori | 355
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy